Abstract
Objective The FilmArray Blood Culture Identification (BCID) panel is a rapid microfluidic PCR amplification microbial detection system. Several studies have evaluated its clinical performance on the basis of blood culture bottles containing resins. However, proportion of hospitals in China use bottles with carbon power, which the performance of FilmArray has not been fully investigated. Therefore, this study is conducted to explore the accuracy of the panel using blood culture bottles with carbon power.
Method 147 venous blood cultures containing carbon powder were used to assess the microbial and antibiotic resistance detection ability of the FilmArray panel. Outcomes were compared with results of the clinical combination method and their consistency was analyzed.
Results FilmArray detected single microorganism in 121 samples, multiple microorganism in 9 cases and the consistency rate between the two methods was 90.6%. Among the 150 microorganisms detected, 85.1% (40/47) of staphylococcus contained the antibiotic resistant mecA gene, 15.3% (9/59) of Enterobacter detected the KPC gene, 7.7% (1/13) of Enterococcus has the vanA gene and the consistency with their clinical drug-resistant phenotypes were 93.6%, 86.4% and 100%, respectively.
Conclusion The identification rate of the FilmArray BCID panel using venous blood cultures with activated carbon powder was highly consistent with the outcomes of previous researchers using non-carbon powder blood culture bottles. It is capable of providing rapid and reliable results in the detection of pathogens present in automated blood culture systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the Biomedical Research Ethics Committee of the PLA General Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors